Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one tenth the standard dose.

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac, a deal that was announced in June.

Under the deal, which was first announced in September, Novartis will pay Arrowhead $200 million upfront. Arrowhead is eligible for additional payments of up to $2 billion tied to development, ...

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

NEW YORK – Galapagos on Tuesday said that after a strategic review it has decided to wind down its cell therapy business, which includes several CAR T-cell therapies in development for blood cancers ...

In this tough-to-treat cancer type, more patients receiving anzu-cel saw their tumors shrink and had durable responses than what's been seen with other therapies.

The Sweden-based Phase II trial will evaluate how well the company's gallium-68-labeled PET tracer identifies best responders to Enhertu.

The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.